Novo Nordisk has made its smart insulin ... The new devices – NovoPen 6 and NovoPen Echo Plus – are insulin self-injection pens that record information such as when and how much insulin ...

Novo Nordisk NVO has integrated its smart insulin pens, NovoPen 6 and NovoPen Echo Plus, with the Dexcom G7 continuous glucose monitoring system. This collaboration enables users to seamlessly ...

LONDON, April 24 (Reuters) - Since launching its wildly popular weight-loss drug Wegovy in 2021, Novo Nordisk (NOVOb.CO), opens new tab has raised its annual sales guidance several times a year.

Novo Nordisk (NYSE: NVO), the Danish drugmaker that's been riding high ever since it began putting out Ozempic and Wegovy GLP-1 injectables for treatment of diabetes and weight loss, got another ...

Novo Nordisk has submitted an "Ozempic pill" to the FDA for approval. The new pill will probably be popular (if approved). However, making it will require Novo Nordisk to ramp up semaglutide ...

Novo Nordisk A/S (NVO) is a high-quality biopharma company that has been a growth play well before its recent obesity drug hit. Shares were hyped a while ago, but have now declined so much that ...

Investing.com -- Novo Nordisk (NYSE:NVO) shares sank more than 7% in Copenhagen after Eli Lilly (NYSE:LLY) released promising trial results for its experimental obesity pill, orforglipron ...

Novo Nordisk’s insulin brand Mixtard will continue ... Diabetologist V Mohan said that people who were using the more expensive pen device could shift to a next-generation insulin that was ...

Novo Nordisk NOVO.B-0.10%decrease; red down pointing triangle shares fell Tuesday after Eli Lilly LLY 1.39%increase; green up pointing triangle announced results of a new pill that could rival the ...

Novo Nordisk's shares fell on news of a clinical success from its biggest rival. As a result, it could lose market share in an important area. However, there are still strong reasons to invest in ...

Lexicon Pharmaceuticals’ pursuit of the last word in obesity candidates has attracted Novo Nordisk. The Danish drugmaker is betting $75 million in upfront and near-term milestone payments to ...